口腔疾病防治 ›› 2021, Vol. 29 ›› Issue (2): 124-129.doi: 10.12016/j.issn.2096-1456.2021.02.010

• 综述 • 上一篇    下一篇

Toll样受体在放化疗诱导的消化道黏膜炎中的作用

嵇灵1(),王甲河1,王建涛2,王艳3()   

  1. 1.口腔疾病研究国家重点实验室 国家口腔疾病临床研究中心 四川大学华西口腔医院,四川 成都(610041)
    2.生物治疗国家重点实验室 四川大学华西医院肺癌中心 四川大学华西医院放疗中心,四川 成都(610041)
    3.口腔疾病研究国家重点实验室 国家口腔疾病临床研究中心 四川大学华西口腔医院儿童口腔科,四川 成都(610041)
  • 收稿日期:2020-05-18 修回日期:2020-07-18 出版日期:2021-02-20 发布日期:2020-12-21
  • 通讯作者: 王艳 E-mail:417978541@qq.com;wangyan1458@scu.edu.cn
  • 作者简介:嵇灵,本科,Email: 417978541@qq.com
  • 基金资助:
    国家自然科学基金项目(81600864);四川省卫计委基金普及项目(18PJ186)

The role of Toll-like receptors in chemoradiotherapy-induced gastrointestinal mucositis

JI Ling1(),WANG Jiahe1,WANG Jiantao2,Wang Yan3()   

  1. 1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
    2. State key Laboratory of Biotherapy & Department of Lung Cancer Center and Department of Radiation Oncology & West China Hospital, Sichuan University, Chengdu 610041, China
    3. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Pediatric Dentistry West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2020-05-18 Revised:2020-07-18 Online:2021-02-20 Published:2020-12-21
  • Contact: Yan Wang E-mail:417978541@qq.com;wangyan1458@scu.edu.cn
  • Supported by:
    grants from National Natural Science Foundation of China(81600864);Scientific Research Foundation of the Health Planning Committee of Sichuan(18PJ186)

摘要:

黏膜炎是肿瘤患者进行放化疗时常见的消化道并发症,包括口腔黏膜炎和胃肠道黏膜炎,临床表现为口腔溃疡、呕吐、腹泻和疼痛等症状,严重降低患者的生活质量,甚至影响抗癌治疗。Toll样受体(Toll-like receptor,TLR)是参与天然免疫的重要受体,通过介导微生物与宿主之间的作用参与放化疗诱导黏膜炎的发生发展。文本针对现有TLR与黏膜炎相关研究予以综述。文献复习结果表明,不同TLR在放化疗诱导的黏膜炎中作用不同:TLR2是放化疗诱导的黏膜炎发生中炎性级联反应的重要受体;TLR4的激活能增加胃肠道黏膜炎症反应以及导致口腔上皮溃疡形成;TLR5激动剂能够降低放疗诱导的黏膜炎损伤程度;拮抗或敲除TLR9可减轻放化疗诱导的胃肠道黏膜炎。然而,目前尚未有TLR相关激动剂或抑制剂应用于临床,未来需要更多的研究对不同TLR在黏膜炎中的作用进行探讨,为放化疗性黏膜炎的精准防治提供参考。

关键词: Toll样受体; Toll样受体; 口腔黏膜炎; 口腔黏膜炎; 胃肠道黏膜炎; 胃肠道黏膜炎; 化疗; 化疗; 放疗; 放疗; Toll样受体2; Toll样受体2; Toll样受体4; Toll样受体4; Toll样受体5; Toll样受体5; Toll样受体9; Toll样受体9

Abstract:

Mucositis is a common gastrointestinal complication in cancer patients undergoing chemoradiotherapy, including oral mucositis and gastrointestinal mucositis, with clinical manifestations of oral ulcers, vomiting, diarrhea and pain that seriously reduce the quality of life of patients and even affect anticancer therapy. Toll-like receptor (TLR) are important receptors involved in innate immunity and in the development of chemoradiation-induced mucositis by mediating the effect between microorganisms and the host. A comprehensive understanding of the role of TLR in mucositis is helpful to guide the prevention and treatment of mucositis. This paper reviews the available studies on TLR and mucositis. The results of the literature review indicate that different TLR have different roles in chemoradiation-induced mucositis: TLR2 is an important receptor in the inflammatory cascade of chemoradiation-induced mucositis; TLR4 activation can increase gastrointestinal mucosal inflammation and lead to oral epithelial ulceration; TLR5 agonists can reduce the degree of radiation-induced mucositis damage; and antagonizing or knocking out TLR9 can reduce chemoradiation-induced gastrointestinal mucositis. However, no TLR agonists or inhibitors have yet been applied in clinical practice, and additional studies are needed to explore the role of different TLR in mucositis in the future to provide a reference for the precise prevention and treatment of chemoradiation-induced mucositis.

Key words: Toll-like receptor (TLR); Toll-like receptor (TLR); oral mucositis; gastrointestinal mucositis; oral mucositis; chemotherapy; gastrointestinal mucositis; radiotherapy; chemotherapy; TLR2; radiotherapy; TLR4; TLR2; TLR5; TLR4; TLR9; TLR5; TLR9

中图分类号: 

  • R781.5